Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+)

Xianglan Lu, Xianfu Wang, Yougmi Kim, Rui Zhang, Shibo Li, Ji-Yun Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene; this fusion gene is usually a consequence of the Philadelphia (Ph+) chromosome, which results from the t(9;22)(q34;q11.2). Patients newly diagnosed with CML are routinely treated with tyrosine kinase inhibitors; however, the clinical course of the disease can vary, and this variance may be associated with genetic heterogeneity. Array comparative genomic hybridization (CGH) technology is a powerful tool for identifying subtle genomic segmental alterations, which can result from either losses or gains of chromosomal material. These changes may reveal the presence of genes that play important roles in disease initiation or progression or in treatment outcomes. To investigate whether subtle somatic copy number changes (CNCs) are commonly present in CML patients, a pilot study of 19 patients with the Ph+ chromosome, but who were negative for common secondary chromosomal anomalies [+der(22), +8, i(17q), and +19], was conducted using a high-density whole genomic oligonucleotide array CGH analysis. Four of the 19 cases had somatic segmental CNCs, including the loss of 9q34, 15q25.3, and 15q13 and a gain of 7p21.1-p15.3. The findings demonstrate that subtle genomic changes are relatively common in CML patients with a Ph+ chromosome and that the clinical significance of these findings, especially the newly discovered regions, must be determined in large patient population studies.

Original languageEnglish
Pages (from-to)513-518
Number of pages6
JournalCancer genetics
Volume205
Issue number10
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative Genomic Hybridization
Gene Fusion
Chromosomes
Genetic Heterogeneity
Oligonucleotide Array Sequence Analysis
Protein-Tyrosine Kinases
Technology
Population
Genes

Keywords

  • ABL1
  • Array CGH
  • BCR
  • CML
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+). / Lu, Xianglan; Wang, Xianfu; Kim, Yougmi; Zhang, Rui; Li, Shibo; Lee, Ji-Yun.

In: Cancer genetics, Vol. 205, No. 10, 01.10.2012, p. 513-518.

Research output: Contribution to journalArticle

Lu, Xianglan ; Wang, Xianfu ; Kim, Yougmi ; Zhang, Rui ; Li, Shibo ; Lee, Ji-Yun. / Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+). In: Cancer genetics. 2012 ; Vol. 205, No. 10. pp. 513-518.
@article{4b89fd73414545b7b748e312267bfe6d,
title = "Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+)",
abstract = "Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene; this fusion gene is usually a consequence of the Philadelphia (Ph+) chromosome, which results from the t(9;22)(q34;q11.2). Patients newly diagnosed with CML are routinely treated with tyrosine kinase inhibitors; however, the clinical course of the disease can vary, and this variance may be associated with genetic heterogeneity. Array comparative genomic hybridization (CGH) technology is a powerful tool for identifying subtle genomic segmental alterations, which can result from either losses or gains of chromosomal material. These changes may reveal the presence of genes that play important roles in disease initiation or progression or in treatment outcomes. To investigate whether subtle somatic copy number changes (CNCs) are commonly present in CML patients, a pilot study of 19 patients with the Ph+ chromosome, but who were negative for common secondary chromosomal anomalies [+der(22), +8, i(17q), and +19], was conducted using a high-density whole genomic oligonucleotide array CGH analysis. Four of the 19 cases had somatic segmental CNCs, including the loss of 9q34, 15q25.3, and 15q13 and a gain of 7p21.1-p15.3. The findings demonstrate that subtle genomic changes are relatively common in CML patients with a Ph+ chromosome and that the clinical significance of these findings, especially the newly discovered regions, must be determined in large patient population studies.",
keywords = "ABL1, Array CGH, BCR, CML, Philadelphia chromosome",
author = "Xianglan Lu and Xianfu Wang and Yougmi Kim and Rui Zhang and Shibo Li and Ji-Yun Lee",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.cancergen.2012.08.004",
language = "English",
volume = "205",
pages = "513--518",
journal = "Cancer genetics",
issn = "2210-7762",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+)

AU - Lu, Xianglan

AU - Wang, Xianfu

AU - Kim, Yougmi

AU - Zhang, Rui

AU - Li, Shibo

AU - Lee, Ji-Yun

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene; this fusion gene is usually a consequence of the Philadelphia (Ph+) chromosome, which results from the t(9;22)(q34;q11.2). Patients newly diagnosed with CML are routinely treated with tyrosine kinase inhibitors; however, the clinical course of the disease can vary, and this variance may be associated with genetic heterogeneity. Array comparative genomic hybridization (CGH) technology is a powerful tool for identifying subtle genomic segmental alterations, which can result from either losses or gains of chromosomal material. These changes may reveal the presence of genes that play important roles in disease initiation or progression or in treatment outcomes. To investigate whether subtle somatic copy number changes (CNCs) are commonly present in CML patients, a pilot study of 19 patients with the Ph+ chromosome, but who were negative for common secondary chromosomal anomalies [+der(22), +8, i(17q), and +19], was conducted using a high-density whole genomic oligonucleotide array CGH analysis. Four of the 19 cases had somatic segmental CNCs, including the loss of 9q34, 15q25.3, and 15q13 and a gain of 7p21.1-p15.3. The findings demonstrate that subtle genomic changes are relatively common in CML patients with a Ph+ chromosome and that the clinical significance of these findings, especially the newly discovered regions, must be determined in large patient population studies.

AB - Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene; this fusion gene is usually a consequence of the Philadelphia (Ph+) chromosome, which results from the t(9;22)(q34;q11.2). Patients newly diagnosed with CML are routinely treated with tyrosine kinase inhibitors; however, the clinical course of the disease can vary, and this variance may be associated with genetic heterogeneity. Array comparative genomic hybridization (CGH) technology is a powerful tool for identifying subtle genomic segmental alterations, which can result from either losses or gains of chromosomal material. These changes may reveal the presence of genes that play important roles in disease initiation or progression or in treatment outcomes. To investigate whether subtle somatic copy number changes (CNCs) are commonly present in CML patients, a pilot study of 19 patients with the Ph+ chromosome, but who were negative for common secondary chromosomal anomalies [+der(22), +8, i(17q), and +19], was conducted using a high-density whole genomic oligonucleotide array CGH analysis. Four of the 19 cases had somatic segmental CNCs, including the loss of 9q34, 15q25.3, and 15q13 and a gain of 7p21.1-p15.3. The findings demonstrate that subtle genomic changes are relatively common in CML patients with a Ph+ chromosome and that the clinical significance of these findings, especially the newly discovered regions, must be determined in large patient population studies.

KW - ABL1

KW - Array CGH

KW - BCR

KW - CML

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=84867672332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867672332&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2012.08.004

DO - 10.1016/j.cancergen.2012.08.004

M3 - Article

C2 - 23036696

AN - SCOPUS:84867672332

VL - 205

SP - 513

EP - 518

JO - Cancer genetics

JF - Cancer genetics

SN - 2210-7762

IS - 10

ER -